The effect of D2E7, a new human anti-TNFα monoclonal antibody, on the oxidative burst of PMN in patients with RA.

被引：0
|
作者：
den Broeder, AA
Wanten, GJA
van Riel, PLCM
Kroot, EJ
Naber, THJ
Barrera, P
机构：
[1] Univ Nijmegen Hosp, Dept Rheumatol, NL-6500 HB Nijmegen, Netherlands
[2] Univ Nijmegen Hosp, Dept Gastroenterol, NL-6500 HB Nijmegen, Netherlands
来源：
ARTHRITIS AND RHEUMATISM | 1998年 / 41卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
150
引用
收藏
页码：S57 / S57
页数：1
相关论文
共 50 条
  • [31] A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-α antibody adalimumab (D2E7) in patients with rheumatoid arthritis
    den Broeder, A
    van de Putte, LBA
    Rau, R
    Schattenkirchner, M
    van Riel, PLCM
    Sander, O
    Binder, C
    Fenner, H
    Bankmann, Y
    Velagapudi, R
    Kempeni, J
    Kupper, H
    JOURNAL OF RHEUMATOLOGY, 2002, 29 (11) : 2288 - 2298
  • [32] Normalization of NOS2 overexpression in rheumatoid arthritis patients treated with anti-TNF monoclonal antibody (cA2).
    Perkins, DJ
    St Clair, EW
    Misukonis, MA
    Weinberg, JB
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S58 - S58
  • [33] Golimumab, a human Anti-TNFα monoclonal antibody, injected every 4 weeks:: Efficacy & safety in RA patients previously treated with anti-TNFa agents (GO-A-FTER study)
    Smolen, J.
    Kay, J.
    Doyle, M. K.
    Landewe, R.
    Matteson, E. L.
    Willenhaupt, J.
    Gaylis, N.
    Murphy, F.
    Neal, J.
    Zhou, Y.
    Visvanathan, S.
    Hsia, E. C.
    Rahman, M. U.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S523 - S524
  • [34] Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate
    Torrance, GW
    Tugwell, P
    Amorosi, S
    Chartash, E
    Sengupta, N
    RHEUMATOLOGY, 2004, 43 (06) : 712 - 718
  • [35] Estimating health utility from a physical function assessment in rheumatoid arthritis (RA) patients treated with Adalimumab (D2E7)
    Boggs, R
    Sengupta, N
    Ashraf, T
    VALUE IN HEALTH, 2002, 5 (06) : 452 - 453
  • [36] A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease.
    McCabe, RP
    Woody, J
    vanDeventer, S
    Targan, SR
    Mayer, L
    vanHogezand, R
    Rutgeerts, P
    Hanauer, SB
    Podolsky, D
    Elson, CO
    GASTROENTEROLOGY, 1996, 110 (04) : A962 - A962
  • [37] Rapid response to human anti-TNF monoclonal antibody adalimumab in patients with moderate to severely active Crohn's disease in the CLASSIC study
    Hanauer, SB
    Sandborn, WJ
    Rutgeerts, P
    Fedorak, RN
    Panaccione, R
    Melilli, LE
    Pollack, PF
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S313 - S314
  • [38] Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study
    Takeuchi, Tsutomu
    Yamanaka, Hisashi
    Ishiguro, Naoki
    Miyasaka, Nobuyuki
    Mukai, Masaya
    Matsubara, Tsukasa
    Uchida, Shoji
    Akama, Hideto
    Kupper, Hartmut
    Arora, Vipin
    Tanaka, Yoshiya
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (03) : 536 - 543
  • [39] Anti-TNFα monoclonal antibody (cA2) produces endoscopic healing in patients with treatment-resistant, active Crohn's disease.
    D'Haens, GR
    van Deventer, SJH
    Van Hogezand, R
    Chalmers, DM
    Braakman, TAJ
    Schaible, TF
    Rutgeerts, PJ
    GASTROENTEROLOGY, 1998, 114 (04) : A964 - A964
  • [40] Low dose methotrexate (MTX) suppresses anti-globulin responses and potentiates efficacy of a chimeric monoclonal anti-TNF alpha antibody (cA2) given repeatedly in rheumatoid arthritis (RA).
    Maini, RN
    Breedveld, FC
    Kalden, JR
    Smolen, JS
    Davis, D
    MacFarlane, JD
    Antoni, C
    Leeb, B
    Elliott, MJ
    Woody, JN
    Schaible, TF
    Feldmann, M
    ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 571 - 571
12345